CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics' stock experienced several notable events between May and November 2025. The company announced plans for a $100 million underwritten offering on May 12, 2025. Shares surged over 160% on May 28, 2025, following positive Phase 1 data for CX-2051 and better-than-expected earnings, leading to an upgrade from H.C. Wainwright. On August 13, 2025, an update on the CX-2051 Phase 1 study was provided, with a data update expected in Q1 2026. Q3 2025 financial results were reported on November 6, 2025, showing a revenue decrease and a missed EPS estimate, causing a stock decline. Despite the Q3 miss, H.C. Wainwright raised the price target on November 11, 2025, citing strong demand for the CX-2051 program. As of November 21, 2025, the stock price was $3.88 per share, a significant increase from the previous year. CytomX management actively participated in investor conferences.

As a clinical-stage biopharmaceutical company, CytomX Therapeutics' revenue is primarily generated through collaboration agreements and milestone payments, rather than direct sales. Therefore, traditional demand seasonality is not directly applicable to its products and services.

CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company operating in the Health Care sector, specifically within the Biotechnology: Pharmaceutical Preparations industry. The company utilizes its Probody® therapeutic platform to develop masked, conditionally activated biologics that target the tumor microenvironment, enhancing drug efficacy and reducing systemic toxicity. Its clinical-stage pipeline includes CX-2051, a masked ADC targeting EpCAM; CX-904, a masked T-cell-engaging bispecific antibody targeting EGFR; CX-801, a masked interferon alpha-2b PROBODY® cytokine; BMS-986288, a PROBODY® version of non-fucosylated ipilimumab; and CX-2029, a Probody® drug conjugate targeting CD71.

CytomX Therapeutics is headquartered in South San Francisco, California, and conducts clinical trials across North America and Europe. The company has strategic collaborations with global pharmaceutical leaders, including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna.

CytomX Therapeutics has maintained a generally positive brand reputation due to its focus on oncology innovation and strategic partnerships. Positive Phase 1 data for CX-2051 and favorable analyst coverage have contributed to this reputation. The company's participation in industry conferences and commitment to diversity, equity, and inclusion initiatives also enhance its brand. No major negative events impacted its brand reputation during this period.

Institutional investors hold a significant portion of CytomX Therapeutics' stock, ranging from approximately 49.42% to 66.60%, with major shareholders including VR Adviser, LLC, Fmr Llc, and Tang Capital Management Llc. Insiders own about 1.09% of the stock, with CEO Sean McCarthy holding 0.7%. The general public and retail investors hold between 32.32% and 41%. Joseph Edelman owns the most shares among individual investors.